Company news

Regenxbio Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

REGENXBIO Reports Second Quarter 2020 Financial Results and Operational Highlights

August 5, 2020

REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD

August 3, 2020

REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

July 29, 2020

REGENXBIO Provides Update on Progress of Clinical Programs for Rare Genetic Neurodegenerative Diseases

July 7, 2020

REGENXBIO Reports First Quarter 2020 Financial Results and Operational Highlights

May 6, 2020

REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 23rd Annual Meeting

April 27, 2020

REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD

April 21, 2020

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

March 30, 2020

REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights

February 25, 2020

REGENXBIO To Host Conference Call on February 26 to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights

February 18, 2020

REGENXBIO Announces Presentations at the 16th Annual WORLDSymposium™ 2020

January 28, 2020

REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights

November 4, 2019

REGENXBIO To Host Conference Call on November 5 to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights

October 28, 2019

REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress

October 16, 2019

REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting

October 10, 2019

REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

September 3, 2019

REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD

August 6, 2019

REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector

July 30, 2019

REGENXBIO Expands Pipeline Using NAV Vectors to Deliver Therapeutic Antibodies for the Treatment of Hereditary Angioedema and Neurodegenerative Diseases

July 23, 2019

REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD

May 29, 2019

REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform

May 23, 2019

REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer

April 16, 2019

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting

April 14, 2019

← Newer news releases

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 21 decks. Every deck is listed under its year.